{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-020834","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.667269+00:00","generated_at":"2026-06-22T18:42:46.836216+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CRISPR Q3 net loss $174.5M; exa-cel rolling FDA review starts Nov, EMA/MHRA by year-end","bullets":["CRISPR Q3 net loss $174.5M, cash $1.97B; R&D spend up to $116.6M.","Exa-cel rolling FDA review starts Nov; complete submission due Q1 2023; EMA/MHRA submissions by year-end.","CTX112 (next-gen CAR-T) IND cleared; Phase 1 expected H1 2023.","VCTX211 (T1D stem-cell therapy) CTA cleared by Health Canada.","CTX110 pivotal trial ongoing; CTX130 RMAT designation for CTCL; additional data expected in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-020834","json":"https://secwatch.observer/filing/0000950170-22-020834.json","markdown":"https://secwatch.observer/filing/0000950170-22-020834.md","text":"https://secwatch.observer/filing/0000950170-22-020834.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017022020834/0000950170-22-020834-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017022020834/crsp-20221101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T18:42:46.836216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"85e22998e210b6b29545f1f94842b0d811e1cfb6","claim":"CRISPR Therapeutics AG reported third quarter ended September 30, 2022 results: revenue $0.1 million.","evidence_excerpt":"Revenue: Total collaboration revenue was $0.1 million for the third quarter of 2022, compared to $0.3 mill","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000095017022020834/0000950170-22-020834-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$0.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}